Brad Spellberg Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Todd C. Lee Gabe 🦊 Sébastien Poulin Vance Fowler Amit Achhra, MD PhD MPH Alireza FakhriRavari, PharmD, BCPS, BCIDP, AAHIVP I think we need larger trials in ID. Can't make helpful conclusions when N=200. In S aureus BSI, fosfomycin added to dapto had relative risk of 0.8 (20% risk reduction) in 2 trials (MSSA, MRSA). But 95% CI crosses 1.
Does it work?
academic.oup.com/cid/article/72…
nature.com/articles/s4159…

Brad Spellberg Amit Achhra, MD PhD MPH Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Alireza FakhriRavari, PharmD, BCPS, BCIDP, AAHIVP Vance Fowler My interpretation of dots is as follows:

We were unable to demonstrate superiority using the prespecified DOOR outcome; however, using the traditional regulatory endpoint of TX failure/success, non inferiority would be met within a prespecified margin of 15%.

Such a pleasure to write this with Adam Stewart who did the heavy lifting! My favorite 🤩 topic, CMV. A precursor to the next international guidelines.

Next up at #ESCMIDGlobal2024

Andrea Kwa – post-hoc analysis of CAMERA2 trial data – does in-vitro synergy correlate with clinical outcomes?

CAMERA2 was Vanco versus Vanco plus (flu)cloxacillin for MRSA bacteraemia – JAMA jamanetwork.com/journals/jama/…

#ECCMID2024 Post-hoc analysis #CAMERA2 People who received combo therapy (Vanc/Dapto PLUS Anti-Staph Beta-Lactam) if testing showed synergy then mortality improved but not amongst those without synergy.

Non inferior also on just clinical efficacy

Similar AE rates. Slighly more AEs leading to discontinuation in SOC arm

Great study!

Provides much stronger evidence to support dalbavancin!

MSSA and MRSA subgroups not reported yet. Longer term follow-up to day 180 to come.

Jean-Claude Mézières

Insane! #recognizeIDinSpain #IDTwitter #MedTwitter Gabe 🦊

🔥DOTS🔥
The most anticipated RCT #ESCMIDGLOBAL2024 Dalbavancin is non-inferior to SOC by clinical efficacy for complicated SAB incl Rt sided IE
2 doses Dalba 1500 mg on days 1 & 8 or 4-8 wks of SOC(cefaz or naf:MSSA;vanc or dapto:MRSA)
DOOR at D70
Slides shared by Alireza FakhriRavari, PharmD, BCPS, BCIDP, AAHIVP

Sneak peak of 🆕️🔥 IDSA/ ESCMID SAB guidelines
🔆Risk stratification,high or low instead of complicated/uncomplicated
🔆Patients with high-risk features at baseline but TTE & PET/CT are negative, short course 14d
Slides shared Sean Ong
#ESCMIDGLOBAL2024
Oral Abx?!

Que pensais? Influye el horario en la respuesta de las vacunas? #vaccine #vacunas #Ciencia SEIP Comité Vacunas - AEP EnFamilia AEP Real Academia de Medicina y Cirugía de Sevilla Pediatría y Áreas Específicas HUVR HospitalUVRocio Facultad de Medicina de Sevilla IBiS SEIMC SEInmunología

Another nail in the vancomycin coffin. After accounting for laboratory testing, pharmacist management time, and costs associated with vancomycin associated AKI, daptomycin saved $166 per patient when used in place of vancomycin. academic.oup.com/ofid/advance-a…

Excellent summary of a clinical trial likely to change clinical practice.

Can't wait to see the full study.